Increased cysteinyldopa plasma levels hint to melanocyte as stress sensor in psoriasis

Experimental Dermatology

Volumn 20, Issue 3, 2011, Pages 288-290

  Panzella, Lucia ^a   Wakamatsu, Kazumasa ^b   Monfrecola, Giuseppe ^a   Ito, Shosuke ^b   Ayala, Fabio ^a   Napolitano, Alessandra ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Cysteinyldopa; Lipid peroxidation markers; Melanocyte; Plasma; Psoriasis

Indexed keywords

CYSTEINYLDOPA; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LETTER; LIPID PEROXIDATION; MALE; MELANOCYTE; PSORIASIS; PSORIASIS SEVERITY INDEX; STRESS;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD; CYSTEINYLDOPA; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MELANOCYTES; MIDDLE AGED; PSORIASIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 79951625205     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01211.x     Document Type: Letter

References (30)

1. Zhou Q, Mrowietz U, Rostami-Yazdi M. Free Radic Biol Med 2009: 47: 891-905.
2. Rashmi R, Rao K S J, Basavaraj K H. Clin Exp Dermatol 2009: 34: 658-663.
3. Yildirim M, Inaloz H S, Baysal V et al. J Eur Acad Dermatol Venereol 2003: 17: 34-36.
4. Tekin N S, Tekin I O, Barut F et al. Mediators Inflamm 2007: 2007: 78454.
5. Woźniak A, Drewa G, Krzyzyńska-Maliniowska E et al. Med Sci Monit 2007: 13: CR30-CR33.
6. Baer A N, Costello P B, Green F A. J Lipid Res 1990: 31: 125-130.
7. Brajac I, Kastelan M, Prpić-Massari L et al. Med Hypotheses 2009: 73: 254-256.
8. Wolber R, Schlenz K, Wakamatsu K et al. Pigment Cell Melanoma Res 2008: 21: 487-491.
9. Costin G E, Hearing V J. FASEB J 2007: 21: 976-994.
10. Tsatmali M, Ancans J, Thody A J. J Histochem Cytochem 2002: 50: 125-133.
11. Rorsman H. Pigment Cell Res 2004: 17: 191-202.
12. Benathan M, Labidi F. Arch Dermatol Res 1996: 288: 697-702.
13. Nimmo J E, Gawkrodger D J, O'Docherty C S et al. Br J Dermatol 1988: 118: 487-495.
14. Wakamatsu K, Ito S. Pigment Cell Res 2006: 19: 460-464.
15. Tegner E, Rorsman H, Rosengren E. Acta Derm Venereol 1983: 63: 21-25.
16. Kikuchi K, Wakamatsu K, Tada Y et al. Clin Exp Dermatol 2008: 33: 750-753.
17. Wakamatsu K, Kageshita T, Furue M et al. Melanoma Res 2002: 12: 245-253.
18. Murakami K, Wakamatsu K, Nakanishi Y et al. Blood Purif 2007: 25: 483-489.
19. Murakami K, Nakanishi Y, Wakamatsu K et al. Blood Purif 2009: 28: 209-215.
20. Chioccara F, Novellino E. Synth Commun 1986: 16: 967-971.
21. Wakamatsu K, Ito S. Clin Chem 1994: 40: 495-496.
22. Wong S H, Knight J A, Hopfer S M et al. Clin Chem 1987: 33: 214-220.
23. Kilinc Karaarslan I, Girgin Sagin F, Ertam I et al. J Eur Acad Dermatol Venereol 2006: 20: 1226-1231.
24. Scott G A, Jacobs S E, Pentland A P. J Invest Dermatol 2006: 126: 855-861.
25. Yoshida M, Takahashi Y, Inoue S J. Invest Dermatol 2000: 114: 334-342.
26. Ito S, Fujita K. Biochem Pharmacol 1982: 31: 2887-2889.
27. Ito S, Fujita K. Biochem Pharmacol 1984: 33: 2193-2197.
28. Slominski A. Exp Dermatol 2009: 18: 760-763.
29. Slominski A, Paus R, Schadendorf D. J Theor Biol 1993: 164: 103-120.
30. Portugal-Cohen M, Soroka Y, Ma'or Z et al. Exp Dermatol 2009: 18: 781-788.